PMID- 27862498
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20231011
IS  - 1365-2184 (Electronic)
IS  - 0960-7722 (Print)
IS  - 0960-7722 (Linking)
VI  - 50
IP  - 1
DP  - 2017 Feb
TI  - All-trans retinoic acid preconditioning enhances proliferation, angiogenesis and 
      migration of mesenchymal stem cell in vitro and enhances wound repair in vivo.
LID - 10.1111/cpr.12315 [doi]
LID - e12315
AB  - OBJECTIVES: Stem cell therapy is considered to be a suitable alternative in 
      treatment of a number of diseases. However, there are challenges in their 
      clinical application in cell therapy, such as to reduce survival and loss of 
      transplanted stem cells. It seems that chemical and pharmacological 
      preconditioning enhances their therapeutic efficacy. In this study, we 
      investigated effects of all-trans retinoic acid (ATRA) on survival, angiogenesis 
      and migration of mesenchymal stem cells (MSCs) in vitro and in a wound-healing 
      model. MATERIALS AND METHODS: MSCs were treated with a variety of concentrations 
      of ATRA, and mRNA expression of cyclo-oxygenase-2 (COX-2), hypoxia-inducible 
      factor-1 (HIF-1), C-X-C chemokine receptor type 4 (CXCR4), C-C chemokine receptor 
      type 2 (CCR2), vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2) 
      and Ang-4 were examined by qRT-PCR. Prostaglandin E2 (PGE2) levels were measured 
      using an ELISA kit and MSC angiogenic potential was evaluated using 
      three-dimensional tube formation assay. Finally, benefit of ATRA-treated MSCs in 
      wound healing was determined with a rat excisional wound model. RESULTS: In 
      ATRA-treated MSCs, expressions of COX-2, HIF-1, CXCR4, CCR2, VEGF, Ang-2 and 
      Ang-4 increased compared to control groups. Overexpression of the related genes 
      was reversed by celecoxib, a selective COX-2 inhibitor. Tube formation and in 
      vivo wound healing of ATRA-treated MSCs were also significantly enhanced compared 
      to untreated MSCs. CONCLUSION: Pre-conditioning of MSCs with ATRA increased 
      efficacy of cell therapy by activation of survival signalling pathways, trophic 
      factors and release of pro-angiogenic molecules.
CI  - (c) 2016 John Wiley & Sons Ltd.
FAU - Pourjafar, M
AU  - Pourjafar M
AD  - Research Center for Molecular Medicine, Hamedan University of Medical Sciences, 
      Hamedan, Iran.
FAU - Saidijam, M
AU  - Saidijam M
AD  - Research Center for Molecular Medicine, Hamedan University of Medical Sciences, 
      Hamedan, Iran.
FAU - Mansouri, K
AU  - Mansouri K
AD  - Medical Biology Research Center, Kermanshah University of Medical, Sciences, 
      Kermanshah, Iran.
FAU - Ghasemibasir, H
AU  - Ghasemibasir H
AD  - Department of Pathology, Hamedan University of Medical Sciences, Hamedan, Iran.
FAU - Karimi Dermani, F
AU  - Karimi Dermani F
AD  - Research Center for Molecular Medicine, Hamedan University of Medical Sciences, 
      Hamedan, Iran.
FAU - Najafi, R
AU  - Najafi R
AD  - Research Center for Molecular Medicine, Hamedan University of Medical Sciences, 
      Hamedan, Iran.
AD  - Endometrium and Endometriosis Research Center, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
LA  - eng
SI  - GENBANK/NM_017232
SI  - GENBANK/NM_024359
SI  - GENBANK/NM_022205
SI  - GENBANK/NM_021866
SI  - GENBANK/NM_001287107
SI  - GENBANK/NM_134454
SI  - GENBANK/NM_001106526
SI  - GENBANK/NR_046237
PT  - Journal Article
DEP - 20161110
PL  - England
TA  - Cell Prolif
JT  - Cell proliferation
JID - 9105195
RN  - 0 (CXCR4 protein, mouse)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 0 (Receptors, CXCR4)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 5688UTC01R (Tretinoin)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
SB  - IM
MH  - Animals
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Cyclooxygenase 2/chemistry/genetics/metabolism
MH  - Cyclooxygenase 2 Inhibitors/pharmacology
MH  - Enzyme Activation/drug effects
MH  - Femur/cytology
MH  - Hypoxia-Inducible Factor 1/genetics/metabolism
MH  - Male
MH  - Mesenchymal Stem Cells/*cytology/*drug effects/metabolism
MH  - Neovascularization, Physiologic/*drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, CXCR4/genetics/metabolism
MH  - Signal Transduction/drug effects
MH  - Skin/pathology
MH  - Tretinoin/*pharmacology
MH  - Vascular Endothelial Growth Factor A/genetics/metabolism
MH  - Wound Healing/*drug effects
PMC - PMC6529123
OTO - NOTNLM
OT  - All-trans retinoic acid
OT  - cyclooxygenase-2
OT  - mesenchymal stem cells
OT  - prostaglandin E2
OT  - stem cell therapy
COIS- The authors declare no conflict of interests related to this study.
EDAT- 2016/11/20 06:00
MHDA- 2017/02/07 06:00
PMCR- 2016/11/10
CRDT- 2016/11/19 06:00
PHST- 2016/08/04 00:00 [received]
PHST- 2016/10/10 00:00 [accepted]
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
PHST- 2016/11/19 06:00 [entrez]
PHST- 2016/11/10 00:00 [pmc-release]
AID - CPR12315 [pii]
AID - 10.1111/cpr.12315 [doi]
PST - ppublish
SO  - Cell Prolif. 2017 Feb;50(1):e12315. doi: 10.1111/cpr.12315. Epub 2016 Nov 10.